Acute ischemic stroke: Overview of recent therapeutic developments

Annual Review of Medicine

Volumn 58, Issue , 2007, Pages 89-106

  Suwanwela, Nijasri ^a   Koroshetz, Walter J ^b  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clot retrieval; Hemorrhage; Intracranial clot lysis; Perfusion mismatch; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CITICOLINE; DISUFENTON SODIUM; GADOLINIUM; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROUROKINASE; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ANGIOGRAPHY; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE COURSE; ECHOENCEPHALOGRAPHY; EMERGENCY CARE; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; NEUROIMAGING; NEUROPROTECTION; PATHOPHYSIOLOGY; PATIENT CARE; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; BRAIN ISCHEMIA; DRUG ADMINISTRATION; METHODOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY;

ANGIOPLASTY, BALLOON; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34047103073     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.58.070605.115306     Document Type: Review

References (62)

1. American Heart Association. 2003. Heart Disease and Stroke Statistics - 2004 Update. Dallas, TX: Am. Heart Assoc.
2. Fang J, Alderman MH. 2001. Trend of stroke hospitalization, United States, 1988-1997. Stroke 32:2213-20
3. Adams H, Adams R, Del Zoppo G, Goldstein LB. 2005. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36:916-21
4. Adams HP, Adams RJ, Brott T, et al. 2003. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 34:1056-83
5. Baron JC. 2001. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc. Dis. 11(Suppl. 1):2-8
6. Ay H, Koroshetz WJ, Benner T, et al. 2005. Transient ischemic attack with infarction: a unique syndrome? Ann. Neurol. 57:679-86
7. Clark W, Wissman S, Albers GW, et al. 1999. Recombinant tissue plasminogen activator (Alteplase) for ischemic stroke within 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA 282:2019-26
8. National Institute of Neurological Disorders and Stroke, rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333:1581-87
9. Kapral MK, Laupacis A, Phillips SJ, et al. for the investigators of the registry of the Canadian Stroke Network. 2004. Stroke care delivery in institutions participating in the registry of the Canadian Stroke Network. Stroke 35:1756-62
10. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. 2005. Thrombolytic therapy in acute ischemic stroke in Asia. The first prospective evaluation. Clin. Neurol. Neurosurg. E-pub ahead of print. doi:10.1016/j.clineuro.2005.09.008
11. Bateman BT, Schumacher HC, Boden-Albala B, et al. 2006. Factors associated with inhospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the Nationwide Inpatient Sample 1999-2002. Stroke 37:440-46
12. Hacke W, Kaste M, Fieschi C, et al. 1995. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke. JAMA 274:1017-25
13. Hacke W, Donnan G, Fieschi C, et al. 2004. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-74
14. Smith EE, Abdullah A, Petkovska I, et al. 2005. Outcomes in patients who do not receive tPA because of mild or improving ischemic stroke. Stroke 36:2497-99
15. Katzin IL, Hammer MD, Furlan AJ, et al., Cleveland Clinic Health System Stroke Quality Improvement Team. 2003. Quality improvement and tissue type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 34:2847-50
16. Schwamm LH, Rosenthal ES, Hirschberg A, et al. 2004. Virtual telestroke support for the emergency department evaluation of acute stroke. Acad. Emer. Med. 11:1193-97
17. Gilligan AK, Thrift AG, Sturm JW, et al. 2005. Stroke units, tissue plasminogen activator, aspirin and neuroprotection: Which stroke intervention could provide the greatest community benefit? Cerebrovasc. Dis. 20:239-44
18. Dey P, Woodman M, Gibbs A, et al. 2005. Early assessment by a mobile stroke team: a randomized controlled trial. Age and Ageing. 34:331-38
19. Kalra L, Evans A, Perez L, et al. 2005. A randomized controlled comparison of alternative strategies in stroke care. Health Technol. Assess. 9:1-94
20. Langhorne P, Taylor G, Murray G, et al. 2005. Early supported discharge services for stroke patients: a meta-analysis of individual patients' data. Lancet 363:501-6
21. Del Zoppo GJ, Poeck K, Pessin MS, et al. 1992. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32:78-86
22. Alexandrov AV, Molina CA, Grotta JC, et al., for the CLOTBUST Investigators. 2004. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 351:2170-78
23. Alexandrov AV, Grotta JC. 2002. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 58:862-67
24. Molina CA, Ribo M, Rubiera M, et al. 2006. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 37(2):425-29
25. Daffertshofer M, Gass A, Ringleb P, et al. 2005. Transcranial low-frequency ultrasound mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 36:1441-46
26. Hacke W, Zeumer H, Ferbert A, et al. 1988. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19:1216-22
27. Furlan A, Higashida R, Wechsler L, et al. 1999. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 282:2003-11
28. Suarez JI, Zaidat OO, Sunshine JL, et al. 2002. Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes. Neurosurgery 50:251-60
29. Rordorf G, Cramer S, Efird JT, et al. 1997. Pharmacologic elevation of blood pressure in acute stroke: clinical effects and safety. Stroke 28:2133-38
30. Greer DM, Lev MH, Cullen S, et al. 2004. MRI improves detection of intracerebral hemorrhage over CT following intra-arterial thrombolysis. Stroke 35(2):491-95
31. Lewandowski CA, Frankel M, Tomsick TA, et al. 1999. Combined intravenous and intraarterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30:2598-605
32. The IMS Study Investigators. 2004. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 35:904-11
33. Smith WS, Sung G, Starkman S, et al. 2005. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36:1432-38
34. Levy EI, Ecker R, Horowitz MB, et al. 2006. Stent-assisted intracranial recanalization for acute stroke: early results. Neurosurgery 58:458-63
35. Barber PA, Demchuk AM, Zhang J, Buchan AM. 2000. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS Study Group. Lancet 355:1670-74
36. Dzialowski I, Hill M, Coutts SB, et al. 2006. Extent of early ischemic changes on computed tomography before thrombolysis: prognostic value of the Alberta Stroke Program Early CT score in ECASS II. Stroke 37:973-78
37. Lev MH, Farkas J, Rodriguez V, et al. 2001. CT angiography in the rapid triage of patients with hyperacute stroke: accuracy in the detection of large vessel thrombus. J. Compu. Axial Tomogr. 25:520-28
38. Sorensen AG, Copen WC, Ostergaard L, et al. 1999. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative blood flow and mean tissue transit time. Radiology 210:519-27
39. Guadeagno JV, Warburton EA, Aigbirhio FI, et al. 2004. Does the acute diffusion-weighted imaging lesion represent penumbra as well as core? A combined quantitative PET/MRI voxel-based study. J. Cerebr. Blood Flow Metabol. 24:1249-54
40. Grant PE, He J, Halpern EF, et al. 2001. Frequency and clinical context of decreased apparent diffusion coefficient reversal in the human brain. Radiology 221:43-50
41. Mullins ME, Schaefer PW, Halpern EF, et al. 2002. Neuroimaging of acute stroke: a study of 691 emergency department cases. Radiology 224(2):353-60
42. Schwamm L, Koroshetz WJ, Sorensen AG, et al. 1998. Time course of lesion development in patients with acute stroke: serial diffusion and hemodynamic-weighted magnetic resonance imaging. Stroke 29:2268-76
43. Rordorf G, Koroshetz WJ, Copen WA, et al. 1998. Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI. Stroke 29:939-43
44. Sobesky J, Wever OZ, Lehnhardt FG, et al. 2005. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 36:980-85
45. Ay H, Schaefer PM, Furie KL, et al. 2002. "Footprints" of transient ischemic attacks: a diffusion-weighted MRI study. Cerebrovasc. Dis. 14:177-86
46. Chalela JA, Alsop DC, Gonzalez-Atavales JB, et al. 2000. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 31:680-87
47. Lev MH, Segal AZ, Farkas J, et al. 2001. Utility of perfusion weighted CT imaging in acute MCA stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke 32:2021-28
48. Wintermark M, Flanders AE, Velthuis B, et al. 2006. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 37:979-85
49. Hacke W, Albers G, Al-Rawi Y, et al. 2005. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36:66-73
50. Albers G. 2006. Results of the DEFUSE trial. Presented at Int. Stroke Conf., Kissimmee, FL
51. Lees KR, Zivin JA, Ashwood T, et al., Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. 2006. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354(6):588-600
52. Saver JL, Kidwell C, Eckstein M, Starkman S, FAST-MAG Pilot Trial Investigators. 2004. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 35(5):e106-108
53. Singhal AB, Benner T, Roccatagliata L, et al. 2005. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke 36:797-802
54. Publication Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. 1998. Low molecular weight heparinoid, ORG 10172 danaparoid, and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 2729:1265-72
55. International Stroke Trial Collaborative Group. 1997. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 349:1569-81
56. Kay R, Wong KS, Yu YL, et al. 1995. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N. Engl. J. Med. 333:1588-93
57. Wong KSL. 2006. Results of the Fraxiparin in Stroke Study. Presented at Int. Stroke Conf., Kissimmee, FL
58. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. 2000. Low molecular weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 355:1205-10
59. Camerlingo M, Salvi P, Belloni G, et al. 2005. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 36:2415-20
60. CAST (Chinese Acute Stroke Trial) Collaborative Group. 1997. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 349(9066):1641-49
61. Kondziolka D, Steinberg GK, Wechsler L, et al. 2005. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J. Neurosur. 103(1):38-34
62. Shyu WC, Lin SZ, Lee CC, et al. 2006. Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. Can. Med. Assoc. J. 174:927-33